NDAORALCAPSULE
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
VRAYLAR (cariprazine) by AbbVie. Approved for schizophrenia, bipolar i disorder, bipolar disorder. First approved in 2015.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VRAYLAR (cariprazine) is an oral atypical antipsychotic approved by the FDA in September 2015 for the treatment of schizophrenia and bipolar disorder. As an atypical antipsychotic, it works by modulating dopamine and serotonin neurotransmission in the brain. The product is positioned in the competitive atypical antipsychotic class, competing against established agents like aripiprazole, risperidone, and olanzapine.
$0.9BPart D
3.9 years to LOEMechanism of Action
Pharmacologic Class:
Atypical Antipsychotic
Indications (3)
Worked on VRAYLAR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.